Terug
Ook genoteerd als
MTHRY
OTC
Dagbereik
€ 11,00
€ 11,00
52-Weeksbereik
€ 9,45
€ 15,25
Volume
300
50D / 200D Gem.
€ 12,02
/
€ 13,38
Vorige Slotkoers
€ 11,00
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 0,2 | 0,4 |
| P/B | 0,0 | 2,9 |
| ROE % | 11,1 | 3,8 |
| Net Margin % | 14,2 | 3,9 |
| Rev Growth 5Y % | 13,9 | 10,0 |
| D/E | 0,1 | 0,2 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 121,57
€ 118,57 – € 127,11
|
520 B | 1 |
| FY2029 |
€ 107,85
€ 105,19 – € 112,77
|
470 B | 1 |
| FY2028 |
€ 93,04
€ 90,74 – € 97,28
|
430 B | 1 |
Belangrijkste Punten
Revenue grew 13,91% annually over 5 years — strong growth
Earnings declined -10,57% over the past year
ROE of 11,09% — decent returns on equity
Debt/Equity of 0,06 — conservative balance sheet
Generating 42,75B in free cash flow
P/E of 0,18 — trading at a low valuation
Groei
Revenue Growth (5Y)
13,91%
Revenue (1Y)19,26%
Earnings (1Y)-10,57%
FCF Growth (3Y)-7,10%
Kwaliteit
Return on Equity
11,09%
ROIC11,72%
Net Margin14,21%
Op. Margin22,10%
Veiligheid
Debt / Equity
0,06
Current Ratio2,96
Interest Coverage87,83
Waardering
P/E Ratio
0,18
P/B Ratio0,02
EV/EBITDA-1,64
Dividend Yield0,01%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 19,26% | Revenue Growth (3Y) | 11,10% |
| Earnings Growth (1Y) | -10,57% | Earnings Growth (3Y) | -9,13% |
| Revenue Growth (5Y) | 13,91% | Earnings Growth (5Y) | 1,71% |
| Profitability | |||
| Revenue (TTM) | 284,90B | Net Income (TTM) | 40,48B |
| ROE | 11,09% | ROA | 6,96% |
| Gross Margin | 54,18% | Operating Margin | 22,10% |
| Net Margin | 14,21% | Free Cash Flow (TTM) | 42,75B |
| ROIC | 11,72% | FCF Growth (3Y) | -7,10% |
| Safety | |||
| Debt / Equity | 0,06 | Current Ratio | 2,96 |
| Interest Coverage | 87,83 | Dividend Yield | 0,01% |
| Valuation | |||
| P/E Ratio | 0,18 | P/B Ratio | 0,02 |
| P/S Ratio | 0,03 | PEG Ratio | -2,24 |
| EV/EBITDA | -1,64 | Dividend Yield | 0,01% |
| Market Cap | 7,45B | Enterprise Value | -103,06B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 284,90B | 238,88B | 230,82B | 208,16B | 169,20B |
| Net Income | 40,48B | 45,27B | 49,03B | 63,85B | 37,82B |
| EPS (Diluted) | 59,60 | 66,63 | 72,17 | 93,98 | 55,68 |
| Gross Profit | 154,36B | 140,53B | 135,19B | 123,27B | 103,40B |
| Operating Income | 62,97B | 64,38B | 71,98B | 95,14B | 58,36B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 581,74B | 490,78B | 400,65B | 345,98B | 273,12B |
| Total Liabilities | 168,94B | 124,08B | 91,13B | 82,03B | 65,86B |
| Shareholders' Equity | 378,44B | 351,92B | 302,63B | 257,84B | 199,81B |
| Total Debt | 24,42B | 18,51B | 10,38B | 8,30B | 5,42B |
| Cash & Equivalents | 134,93B | 149,66B | 118,32B | 104,25B | 89,14B |
| Current Assets | 243,43B | 240,74B | 203,47B | 198,87B | 164,11B |
| Current Liabilities | 82,11B | 67,17B | 59,58B | 57,22B | 50,31B |
Strategiescores
This stock passed the criteria for 4 strategies
Score = fit strength (0–100)
Rank = position among all matches
Recente Activiteit
Ingestapt
Cash Flow Compounder
Mar 24, 2026
Ingestapt
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Ingestapt
Defensive Investing (Benjamin Graham)
Mar 24, 2026